These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 1398280

  • 21. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
    Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, Santoro C, Mandelli F.
    Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
    [Abstract] [Full Text] [Related]

  • 22. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ, FOX study investigators.
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [Abstract] [Full Text] [Related]

  • 23. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A.
    Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of essential thrombocythemia with anagrelide.
    Chintagumpala MM, Kennedy LL, Steuber CP.
    J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
    [Abstract] [Full Text] [Related]

  • 28. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.
    N Engl J Med; 2005 Jul 07; 353(1):33-45. PubMed ID: 16000354
    [Abstract] [Full Text] [Related]

  • 29. [Anagrelide for treatment of patients with essential thrombocythaemia].
    Boban A, Sertić D, Radman I, Zupancić-Salek S, Zadro R, Labar B.
    Lijec Vjesn; 2008 Jul 07; 130(5-6):141-5. PubMed ID: 18792562
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
    Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A.
    Med Oncol; 2007 Jul 07; 24(1):63-70. PubMed ID: 17673813
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Anagrelide--new antiplatelet drug].
    Robak T, Treliński J, Hołub A.
    Acta Haematol Pol; 1994 Jul 07; 25(4):309-15. PubMed ID: 7847031
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD.
    Am J Health Syst Pharm; 1998 Oct 01; 55(19):1979-86. PubMed ID: 9784784
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C, Sol EB, Malarme M, Noubouossie D, Demulder AC.
    Clin Ther; 2009 Nov 01; 31(11):2559-64. PubMed ID: 20110000
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.